drugset / Trial / NCT00272493

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

NCT00272493

RandomizedParallel-groupOpen-labelPrevention

Summary

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses. The purpose of this study is to evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response to hepatitis B virus (HBV) vaccination in HIV infected individuals.

Timeline

Start
Primary completion
2007-11
Completion
2008-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hepatitis B vaccine Vaccine 40 ug
Subject sargramostim Protein / enzyme biologic 250 ug